PREMAPROB. Probiotics to Prevent Necrotizing Enterocolitis

NCT06501404 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 583

Last updated 2024-07-15

No results posted yet for this study

Summary

The main objective of this study is to assess the impact of two different doses of a mixture of probiotics from two strains isolated in human milk on the incidence of severe necrotizing enterocolitis (NEC) and death among preterm infants of gestational age less than or equal to 32 weeks of gestation and weighing between 750 and 1500 g.

Conditions

  • Premature Infants
  • Necrotizing Enterocolitis

Interventions

DIETARY_SUPPLEMENT

High dose group

A daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains

DIETARY_SUPPLEMENT

Low dose group

A daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains

Sponsors & Collaborators

  • University Hospital Virgen de las Nieves

    collaborator OTHER
  • Hospital Regional de Malaga

    collaborator OTHER
  • Hospital of Jaen

    collaborator OTHER
  • Hospital Costa del Sol

    collaborator OTHER
  • Hospital Universitario Torrecárdenas

    collaborator OTHER
  • Hospital Universitario Virgen Macarena

    collaborator OTHER
  • Complejo Hospitalario de Especialidades Juan Ramón Jimenez

    collaborator OTHER
  • Hospital Universitario de Valme

    collaborator OTHER
  • Hospitales Universitarios Virgen del Rocío

    collaborator OTHER
  • Hospital Universitario Puerta del Mar

    collaborator OTHER
  • Hospital General Universitario Santa Lucia

    collaborator OTHER
  • Hospital del SAS de Jerez

    collaborator OTHER
  • José Antonio Hurtado Suazo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
72 Hours
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-10
Primary Completion
2015-01-15
Completion
2020-03-20

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06501404 on ClinicalTrials.gov